Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DAVE NASDAQ:NVDA NYSE:SMR NASDAQ:TMDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDAVEDave$276.93+3.0%$226.53$152.21▼$287.69$3.53B3.93559,719 shs697,309 shsNVDANVIDIA$215.59+0.6%$198.67$132.92▼$236.54$5.22T2.25169.74 million shs88.14 million shsSMRNuScale Power$12.88+5.6%$11.40$8.85▼$57.42$4.70B2.2429.11 million shs29.72 million shsTMDXTransMedics Group$67.21-0.9%$93.84$60.10▼$156.00$2.33B2.071.09 million shs532,267 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDAVEDave+4.90%+11.59%-3.49%+39.09%+23.72%NVDANVIDIA+0.78%-2.40%+0.39%+20.92%+58.93%SMRNuScale Power+1.09%+7.08%+2.97%-4.98%-65.63%TMDXTransMedics Group-3.31%-1.48%-33.01%-53.30%-47.26%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDAVEDave$276.93+3.0%$226.53$152.21▼$287.69$3.53B3.93559,719 shs697,309 shsNVDANVIDIA$215.59+0.6%$198.67$132.92▼$236.54$5.22T2.25169.74 million shs88.14 million shsSMRNuScale Power$12.88+5.6%$11.40$8.85▼$57.42$4.70B2.2429.11 million shs29.72 million shsTMDXTransMedics Group$67.21-0.9%$93.84$60.10▼$156.00$2.33B2.071.09 million shs532,267 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDAVEDave+4.90%+11.59%-3.49%+39.09%+23.72%NVDANVIDIA+0.78%-2.40%+0.39%+20.92%+58.93%SMRNuScale Power+1.09%+7.08%+2.97%-4.98%-65.63%TMDXTransMedics Group-3.31%-1.48%-33.01%-53.30%-47.26%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDAVEDave 2.93Moderate Buy$323.4016.78% UpsideNVDANVIDIA 3.00Buy$305.3841.65% UpsideSMRNuScale Power 2.18Hold$15.9223.61% UpsideTMDXTransMedics Group 2.46Hold$134.0099.38% UpsideCurrent Analyst Ratings BreakdownLatest TMDX, NVDA, DAVE, and SMR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2026DAVEDave BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/27/2026NVDANVIDIA Tigress FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingStrong-Buy$360.00 ➝ $425.005/27/2026DAVEDave B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$358.00 ➝ $370.005/27/2026DAVEDave EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageHold$260.005/27/2026NVDANVIDIA Tigress FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetStrong-Buy$360.00 ➝ $425.005/26/2026TMDXTransMedics Group UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold5/26/2026DAVEDave UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral ➝ Buy$300.005/26/2026DAVEDave UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$300.005/26/2026NVDANVIDIA Rothschild & Co RedburnSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$280.00 ➝ $300.005/26/2026TMDXTransMedics Group Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$85.00 ➝ $75.005/22/2026NVDANVIDIA Citic SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$242.00 ➝ $315.00(Data available from 5/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDAVEDave$554.20M6.35$13.91 per share19.91$16.03 per share17.28NVDANVIDIA$215.94B24.16$4.79 per share45.00$8.08 per share26.68SMRNuScale Power$31.48M149.49N/AN/A$3.04 per share4.24TMDXTransMedics Group$605.49M3.84$3.76 per share17.86$14.29 per share4.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDAVEDave$195.87M$15.5517.8415.86N/A37.22%77.70%45.59%8/5/2026 (Estimated)NVDANVIDIA$120.07B$6.5333.0519.810.5162.97%96.94%72.16%N/ASMRNuScale Power-$355.79M-$2.92N/AN/AN/A-2,066.55%-48.88%-38.10%8/6/2026 (Estimated)TMDXTransMedics Group$190.29M$4.4015.3218.57N/A27.04%22.38%8.46%7/30/2026 (Estimated)Latest TMDX, NVDA, DAVE, and SMR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q1 2027NVDANVIDIA$1.76$1.87+$0.11$2.39$78.42 billion$81.62 billion5/7/2026Q1 2026SMRNuScale Power-$0.11-$0.14-$0.03-$0.14$7.00 million$0.57 million5/5/2026Q1 2026DAVEDave$2.86$3.64+$0.78$4.02$153.67 million$158.40 million5/5/2026Q1 2026TMDXTransMedics Group$0.62$0.30-$0.32$0.20$174.44 million$173.93 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDAVEDaveN/AN/AN/AN/AN/ANVDANVIDIA$0.040.02%+14.87%0.61%1 YearsSMRNuScale PowerN/AN/AN/AN/AN/ATMDXTransMedics GroupN/AN/AN/AN/AN/ALatest TMDX, NVDA, DAVE, and SMR DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/20/2026NVDANVIDIAquarterly$0.250.45%6/4/20266/4/20266/26/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDAVEDave0.953.863.86NVDANVIDIA0.043.442.85SMRNuScale PowerN/A29.3629.36TMDXTransMedics Group1.706.746.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDAVEDave18.01%NVDANVIDIA65.27%SMRNuScale Power78.37%TMDXTransMedics Group99.67%Insider OwnershipCompanyInsider OwnershipDAVEDave28.48%NVDANVIDIA3.94%SMRNuScale Power1.28%TMDXTransMedics Group6.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDAVEDave25012.71 million9.09 millionOptionableNVDANVIDIA42,00024.20 billion23.25 billionOptionableSMRNuScale Power440365.48 million360.80 millionOptionableTMDXTransMedics Group21034.56 million32.18 millionOptionableTMDX, NVDA, DAVE, and SMR HeadlinesRecent News About These CompaniesReasons to Retain TransMedics Stock in Your Portfolio for NowMay 28 at 2:01 PM | zacks.comStifel Nicolaus Lowers TransMedics Group (NASDAQ:TMDX) Price Target to $75.00May 26 at 12:09 PM | marketbeat.comTransMedics: Despite Earnings Miss, Growth Story Remains IntactMay 25, 2026 | seekingalpha.comHead to Head Comparison: TransMedics Group (NASDAQ:TMDX) vs. Pressure BioSciences (OTCMKTS:PBIO)May 22, 2026 | americanbankingnews.comTransMedics Shareholders Reelect Board and Approve Executive PayMay 21, 2026 | tipranks.comTransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)May 21, 2026 | prnewswire.comTransMedics Group Signals Growth Amid Margin SqueezeMay 21, 2026 | theglobeandmail.comTransMedics Group (NASDAQ:TMDX) Gains Momentum In Healthcare SpaceMay 19, 2026 | kalkinemedia.comKTransMedics to Present at the William Blair 46th Annual Growth Stock ConferenceMay 19, 2026 | prnewswire.comTransMedics Group (NASDAQ:TMDX) Shares Up 7.1% - Here's What HappenedMay 18, 2026 | marketbeat.comTransMedics Group (TMDX) price target decreased by 22.22% to 126.07May 14, 2026 | msn.comTransMedics Group (NASDAQ:TMDX) Reaches New 52-Week Low - Here's WhyMay 12, 2026 | marketbeat.comAssessing TransMedics Group (TMDX) Valuation After A Sharp One Year Share Price DeclineMay 11, 2026 | finance.yahoo.comWall Street Zen Downgrades TransMedics Group (NASDAQ:TMDX) to SellMay 9, 2026 | marketbeat.comTransMedics Group, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 8, 2026 | seekingalpha.comTransMedics Group Inc (TMDX) Q1 2026 Earnings Call Highlights: Strong Revenue Growth Amid ...May 8, 2026 | finance.yahoo.comTransMedics Group, Inc. (NASDAQ:TMDX) Given Average Rating of "Moderate Buy" by BrokeragesMay 8, 2026 | marketbeat.comTransMedics Group (TMDX) Gets a Buy from NeedhamMay 7, 2026 | theglobeandmail.comTransMedics Group Stock Watch: Healthcare Growth in FocusMay 6, 2026 | kalkinemedia.comKTransMedics tumbles after earnings missMay 6, 2026 | seekingalpha.comTransMedics: Cheaper, But Still Priced For PerfectionMay 6, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines5 Stocks to Buy in May Before the Next AI Surge HitsBy Thomas Hughes | May 1, 2026Beyond NVIDIA: Picks-and-Shovels AI Plays with Strong MomentumBy Chris Markoch | May 10, 2026After NVIDIA, Broadcom's Earnings Are Next—Here's What to WatchBy Leo Miller | May 26, 2026NVIDIA’s China Connection: Investor Risks With Earnings AheadBy Thomas Hughes | May 5, 2026Years in the Making, AMD’s Upside Movement Has Just BegunBy Thomas Hughes | May 6, 2026TMDX, NVDA, DAVE, and SMR Company DescriptionsDave NASDAQ:DAVE$276.93 +8.11 (+3.02%) As of 02:15 PM Eastern This is a fair market value price provided by Massive. Learn more.Dave, Inc. is a digital banking service. Its products include a budgeting tool to help members manage their upcoming bills to avoid overspending, cash advances through its flagship ExtraCash product to help members avoid punitive overdraft fees, a Side Hustle product, where Dave helps connect members with supplemental work opportunities, and Dave Banking, a modern checking account experience with valuable tools for building long-term financial health. The company was founded by Jason Wilk, Paras Chitrakar, and John Wolanin in October 2015 and is headquartered in Los Angeles, CA.NVIDIA NASDAQ:NVDA$215.58 +1.34 (+0.62%) As of 02:15 PM Eastern This is a fair market value price provided by Massive. Learn more.NVIDIA Corporation provides graphics and compute and networking solutions in the United States, Taiwan, China, Hong Kong, and internationally. The Graphics segment offers GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, and solutions for gaming platforms; Quadro/NVIDIA RTX GPUs for enterprise workstation graphics; virtual GPU or vGPU software for cloud-based visual and virtual computing; automotive platforms for infotainment systems; and Omniverse software for building and operating metaverse and 3D internet applications. The Compute & Networking segment comprises Data Center computing platforms and end-to-end networking platforms, including Quantum for InfiniBand and Spectrum for Ethernet; NVIDIA DRIVE automated-driving platform and automotive development agreements; Jetson robotics and other embedded platforms; NVIDIA AI Enterprise and other software; and DGX Cloud software and services. The company's products are used in gaming, professional visualization, data center, and automotive markets. It sells its products to original equipment manufacturers, original device manufacturers, system integrators and distributors, independent software vendors, cloud service providers, consumer internet companies, add-in board manufacturers, distributors, automotive manufacturers and tier-1 automotive suppliers, and other ecosystem participants. NVIDIA Corporation was incorporated in 1993 and is headquartered in Santa Clara, California.NuScale Power NYSE:SMR$12.88 +0.69 (+5.63%) As of 02:15 PM Eastern This is a fair market value price provided by Massive. Learn more.NuScale Power Corporation engages in the development and sale of modular light water reactor nuclear power plants to supply energy for electrical generation, district heating, desalination, hydrogen production, and other process heat applications. It offers NuScale Power Module (NPM), a water reactor that can generate 77 megawatts of electricity (MWe); and VOYGR power plant designs for three facility sizes that are capable of housing from one to four and six or twelve NPMs. The company was founded in 2007 and is headquartered in Portland, Oregon. NuScale Power Corporation operates as a subsidiary of Fluor Enterprises, Inc.TransMedics Group NASDAQ:TMDX$67.21 -0.62 (-0.91%) As of 02:15 PM Eastern This is a fair market value price provided by Massive. Learn more.TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dollar Tree Keeps Winning After Family Dollar Divorce Marvell’s Pullback May Be the Setup Bulls Were Waiting For Snowflake and the Snowballing Impact of its AI Flywheel China Deal Ignites Boeing's Financial Afterburners IREN Is Flipping the Switch from Bitcoin to AI Flight Path to Profits: American Airlines Bets on SpaceX Meta's Manus Mess: Why China Blocked the Deal and What It Means Apple’s Agentic AI Plans Could Be Its Biggest Growth Story Yet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
